Biogen’s Mixed Alzheimer’s Data Leaves Investors Weighing CELIA’s Signal
Biogen’s two-year CELIA data showed broad clinical improvement at 60 mg, but the MMSE exception leaves investors weighing a mixed Alzheimer’s signal.
Bristol Myers Squibb’s KarXT Data Puts Schizophrenia Growth Story in Focus
Preliminary KarXT data puts Bristol Myers Squibb’s psychiatry pipeline under the microscope, with investors watching for evidence that could shape fut…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
GSK Wins FDA Approval for Nelkarmi After $10.6 Billion Nuvalent Acquisition
Nelkarmi’s FDA approval gives GSK an early validation point for its $10.6 billion Nuvalent acquisition and strengthens i…
Rythm Pharmaceuticals Jumps on Reported $150 Offer From Eli Lilly With CVR
Rythm Pharmaceuticals gained after a report of a $150-per-share Eli Lilly offer with a CVR, creating premium potential b…
Cardiff Oncology’s Phase III Push Puts Trial Durability in the Spotlight
Cardiff Oncology’s UBS conference update puts its Phase III timeline—and the durability question—at the center of the CR…
Roche’s FDA Approval Adds Momentum to Its Advanced Breast Cancer Franchise
Roche’s FDA approval for an advanced breast cancer pill gives North American healthcare investors a fresh regulatory cat…
AstraZeneca’s Two FDA Approvals Expand Its U.S. Growth Pipeline
AstraZeneca’s two U.S. FDA approvals broaden its commercial portfolio and give investors a fresh signal on pipeline exec…
Acadia’s Mixed Alzheimer’s Psychosis Readout Keeps ACAD Investors Focused on Phase 3
Acadia’s RADIANT study missed its primary endpoint but hit a key secondary endpoint, leaving ACAD with near-term uncerta…
Aytu BioPharma Buyout Sets $2.70 Per-Share Target for Deal Arbitrage Traders
Rosemont’s proposed acquisition of Aytu BioPharma establishes a fixed $2.70-per-share reference point for AYTU deal anal…
Eli Lilly’s $1.5 Billion Calytrix Deal Signals a Push Beyond Obesity Drugs
Eli Lilly’s up-to-$1.5 billion Calytrix Bio acquisition points to broader pipeline ambitions as biotech consolidation co…
MiniMed Stock Gains as FDA Clearance Puts Tubeless Pump in the Spotlight
MiniMed stock gained after FDA clearance of its tubeless insulin pump, giving the $5.29 billion company a potential near…